Clinical Trial Update: Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer [Phase 3]

View source ↗

Summary

This Phase 3 trial evaluates whether adding bevacizumab to a carboplatin, paclitaxel, and gemcitabine regimen after surgery improves outcomes in patients with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• Gemcitabine (Gemcitabine)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2020-12-14